Table 1.
The immunophenotypes of 42 cases of RCCs with sarcomatoid differentiation and the expression differences between carcinoma and sarcomatoid differentiation
| Markers | C+/S+ | C+/S- | C−/S+ | C−/S- | Total C+ | Total S+ | P value |
|---|---|---|---|---|---|---|---|
| Vimentin | 22 | 0 | 20 | 0 | 22 (52%) | 42 (100%) | 0.000* |
| CK | 18 | 16 | 3 | 5 | 34 (81%) | 21 (50%) | 0.005* |
| EMA | 21 | 16 | 0 | 5 | 37 (88%) | 21 (50%) | 0.000* |
| CK7 | 0 | 11 | 5 | 26 | 11 (26%) | 5 (12%) | 0.164 |
| CK18 | 12 | 13 | 7 | 10 | 25 (60%) | 19 (45%) | 0.275 |
| HMW-CK | 0 | 0 | 3 | 39 | 0 (0%) | 3 (7%) | 0.241 |
| CAIX | 20 | 1 | 12 | 9 | 21 (50%) | 32 (76%) | 0.023* |
| CD10 | 20 | 3 | 12 | 7 | 23 (55%) | 32 (76%) | 0.065 |
| PAX8 | 24 | 10 | 3 | 4 | 34 (81%) | 27 (64%) | 0.141 |
| AMACR | 3 | 8 | 3 | 28 | 11 (26%) | 6 (14%) | 0.277 |
| CD117 | 0 | 7 | 3 | 32 | 7 (17%) | 3 (7%) | 0.313 |
| CD99 | 0 | 3 | 9 | 30 | 3 (7%) | 9 (21%) | 0.116 |
| SMA | 0 | 0 | 8 | 34 | 0 (0%) | 8 (19%) | 0.005* |
| CD34 | 0 | 0 | 0 | 42 | 0 (0%) | 0 (0%) | − |
| S100 | 0 | 0 | 0 | 42 | 0 (0%) | 0 (0%) | − |
| HMB45 | 0 | 0 | 0 | 42 | 0 (0%) | 0 (0%) | − |
| MelanA | 0 | 0 | 0 | 42 | 0 (0%) | 0 (0%) | − |
| P53 | 8 | 2 | 12 | 20 | 10 (24%) | 20 (48%) | 0.040* |
| Bcl-2 | 9 | 16 | 0 | 17 | 25 (60%) | 9 (21%) | 0.001* |
C carcinoma cell, S sarcomatoid cell
*The difference is statistically significant